You searched for "intracameral"

625 results found

RPE tears in cases of IPCV

The aim of this study was to investigate the occurrence, characteristics, management and prognosis of retinal pigment epithelium (RPE) tears in patients with polypoidal choroidal vasculopathy (PCV). Medical records of previous cases were reviewed over an eight-year period from a...

Treat-and-extend regimen in treatment of patients with type 3 neovascularisation

Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...

Tumour deposits following choroidal melanoma treatment

The authors present the unique case of retinoinvasive melanoma following treatment of choroidal melanoma with brachytherapy. Uveal melanoma, the commonest intraocular malignancy in adults, presents as a pigmented mass in the choroid, ciliary body, or iris. A 79-year-old Caucasian male...

Managing cataract surgery in a patient with diabetic maculopathy

A 56-year-old type 2 diabetic with previously treated bilateral diabetic maculopathy develops a cataract requiring surgery in the right eye. He has had grid laser previously, followed intermittently by intravitreal triamcinalone, Avastin and more recently Lucentis in both eyes. His...

How many injections in nAMD: ranibizumab vs. aflibercept

Intravitreal anti-VEGF injections make up a large proportion of the workload in ophthalmology clinics. Since the introduction of aflibercept with eight weekly injections there has been an option to use a treatment which may require less treatment, with potential cost...

Treatment of Type 1 ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone

This is a retrospective review of charts of 54 consecutive very low birth weight (VLBW) infants between June 2011 and January 2015 from Berlin, Germany. Type 1 ROP (posterior ROP, n=33; peripheral zone 2, n= 21) were treated with either...

Detection of antiranibizumab antibodies in exudative AMD

In this study the authors aimed to detect immune response to ranibizumab treatment in wet age-related macular degeneration (AMD). An ELISA was employed to quantify the anti-ranibizumab titre which was compared against the control anti-abciximab titre. Titres of anti-ranibizumab antibodies...

Cystoid macular oedema following cataract surgery

This review covers the history, incidence, diagnosis, risk factors, pathophysiology and medical management of postoperative macular oedema (PCMO), with a particular emphasis on key contemporary studies and novel observations. The authors revisit the incidence of well-established risk factors including intraoperative...

Efficacy of IVC injection in the treatment of ROP

This is a retrospective consecutive case series of patients who received intravitreal conbercept (IVC) as a primary treatment from June 2015 to July 2016 for treatment of retinopathy of prematurity (ROP). Forty-eight eyes of 24 patients were included in the...

Delayed angle closure in pseudophakia and repeated intravitreal therapy

The authors report two cases of acute angle closure many years after uneventful cataract surgery and posterior chamber intraocular lens (IOL) implantation. Both patients had neovascular age-related macular degeneration (AMD) and received regular intravitreal injections (24 and 25 injections in...

Refraction results in ROP with and without IVB

The authors aimed to compare refractive results of intravitreal bevacizumab (IVB) injection in premature neonates with retinopathy of prematurity (ROP) versus infants with spontaneous regression of ROP. The study included 87 infants (174 eyes). Group 1 included 38 infants (76...

Two-year interim safety results of the 0.2ug/day FAC intravitreal implant for the treatment of DMO

This is a 24-month interim prospective observational study of 95 previously steroid challenged patients (115 eyes) receiving intravitreal 0.2ug/day fluocinolone acetaid (FAC) implant for diabetic macular oedema (DMO) treatment. The mean IOP for pre- and post- FAC implants were stable,...